DALLAS and COLUMBUS, Ohio, Sept.
28, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN),
a clinical stage biopharmaceutical company using its proprietary
RADR® artificial intelligence ("A.I.") platform to
transform the cost, pace, and timeline of oncology drug discovery
and development and Deep Lens, a digital healthcare company focused
on enabling faster recruitment of the best-suited cancer patients
for clinical trials at the time of diagnosis, today announced that
they have entered into a strategic collaboration that will leverage
Deep Lens' artificial intelligence clinical trial matching
solution, VIPERÔ, creating an end-to-end A.I. enabled drug
development pathway that is expected to accelerate trial enrollment
for Lantern's planned Phase 2 clinical trial for never-smokers with
non-small cell lung cancer (NSCLC), utilizing LP-300 in combination
with chemotherapy.
![Lantern Pharma (LTRN) Logo (PRNewsfoto/Lantern Pharma) Lantern Pharma (LTRN) Logo (PRNewsfoto/Lantern Pharma)](https://mma.prnewswire.com/media/1216507/Lantern_Pharma_Logo.jpg)
Lantern is developing oncology therapies by leveraging its
proprietary RADR® A.I. platform and machine learning to
discover biomarker signatures that identify patients most likely to
respond to its pipeline of therapeutics. Deep Lens' proprietary
A.I.-based platform, VIPER, identifies, triages and matches cancer
patients to clinical trials in real time for which they may be
eligible. Together, the companies are addressing two of the most
complex and time-consuming parts of the drug development process:
matching a novel molecule with a relevant indication and
identifying the right patients to participate in clinical
trials.
Panna Sharma, President & CEO
of Lantern Pharma, stated, "The current drug development model is
extremely expensive, with an estimated $2.6
billion in drug development costs for each Food and
Drug Administration (FDA)-approved drug. Moreover, based on
the estimated 5.3% success rate for oncology drugs, most therapies,
will fail to reach commercialization, despite showing efficacy in
certain subgroups. Not only do the majority of therapies in
development fail to meet safety or efficacy endpoints, but an
equally large number, 75% of clinical trials, fail to meet
recruitment deadlines, due in large part to enrollment challenges.
It is quite apparent that cancer treatment requires a lower cost of
care and an increase in the choice and efficacy of precision
therapies, which we believe we can deliver through a combination of
A.I., machine learning, and large-scale biomarker analytics, with a
goal of ultimately crushing the cost of cancer therapy development.
For this reason, we are very excited to partner with Deep Lens and
create an end-to-end A.I. enabled pathway from drug rescue to
patient recruitment."
Mr. Sharma continued, "Our existing A.I. platform allows us to
predict drug outcomes and response in very specific patient
subsets, while Deep Lens' VIPER serves as a tool to find and
accelerate the enrollment of appropriate patients for clinical
trials. We believe this accelerated and efficient process will help
more cancer patients to have access to the right medicine at the
right time. We hope to leverage this solution across additional
trials and combine it with other advanced A.I. technologies that
align with our mission of accelerating the timeline and reducing
the costs of oncology drug discovery and development."
Lantern Pharma's approach is to in-license and develop oncology
therapies using genomic data, machine learning, and computational
biology modeling to identify the patient groups most likely to
respond to a therapy, and to clarify the potential underlying
mechanisms of action. Lantern's LP-300 is a small molecule entity
that has been studied in multiple randomized, controlled
multi-center NSCLC trials. In retrospective analyses of a
multi-country Phase 3 trial, LP-300 with chemotherapy demonstrated
substantial improvement in overall survival in the never-smoker
subgroup. LP-300 is currently in preparation to enter a phase 2
clinical trial for use of LP-300 as a combination therapy for
never-smoking NSCLC patients with histologically defined
adenocarcinoma. Deep Lens will utilize the patient enrollment
criteria identified by Lantern to find this subgroup of patients
and match them to the LP-300 clinical trial across Deep Lens'
network of community oncology sites.
"Precision medicine has changed the way we think about treating
and identifying certain types of cancer, but it has also
significantly increased the complexity of clinical trials. Trials
often have very narrow eligibility criteria, making enrollment
objectives difficult to meet, and unfortunately, many companies
will fail to move along the development path successfully," said
Dave Billiter, Chief Executive
Officer and Co-Founder of Deep Lens. "Deep Lens leverages their
A.I. platform, VIPER, and supporting services to automate the
patient identification and screening process, so that trials enroll
faster and more efficiently. We believe that leveraging A.I. across
multiple phases of drug development will decrease overall
time-to-market timelines as well as associated costs. We look
forward to partnering with Lantern to help them achieve their trial
enrollment goals and to provide access to LP-300 to patients in
need as quickly as possible."
Lantern is focused on developing LP-300 as a potential
first-in-class combination therapy for never smoking NSCLC patients
with histologically defined adenocarcinoma. NSCLC among never
smokers has a distinct molecular profile and according to the
American Cancer Society, as many as 20% of people who die from lung
cancer in the United States every
year have never smoked or used any other form of tobacco. Leading
researchers have started to classify lung cancer in never and
non-smokers as having unique and distinct clinical, biological and
pathological characteristics that have the potential to be impacted
by new therapeutic options. According to market research and data
analytics firm, GlobalData, approximately $10 billion was spent on NSCLC therapies in 2020,
across the leading eight markets (by annual drug sales), with
approximately $4 billion of this drug
spend in the U.S. alone.
About Deep Lens
Deep Lens is a digital healthcare company focused on a
groundbreaking approach to faster recruitment of the best-suited
cancer patients to clinical trials. VIPER, Deep Lens' integrated
cloud platform, provides care teams with visibility and workflows
that combine lab, EMR, and genomic data to match cancer patients to
clinical trials and precision therapies at the time of diagnosis,
accelerating recruitment and compressing study timelines to bring
game-changing therapies to market sooner. Growing with sponsors,
providers, and strategic partners, Deep Lens challenges the status
quo so that patients can get the best therapies. For more
information, visit www.deeplens.ai.
About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage oncology-focused
biopharmaceutical company leveraging its proprietary
RADR® A.I. platform and machine learning to discover
biomarker signatures that identify patients most likely to respond
to its pipeline of genomically targeted therapeutics. Lantern is
currently developing four drug candidates and an ADC program across
eight disclosed tumor targets, including two phase 2 programs. By
targeting drugs to patients whose genomic profile identifies them
as having the highest probability of benefiting from the drug,
Lantern's approach represents the potential to deliver
best-in-class outcomes. More information is available at:
www.lanternpharma.com and Twitter @lanternpharma.
Forward-looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements include, among other things, statements relating to:
future events or Lantern's future financial performance; the
potential advantages of Lantern's RADR® platform in
identifying drug candidates and patient populations that are likely
to respond to a drug candidate; Lantern's strategic plans to
advance the development of its drug candidates and antibody drug
conjugate (ADC) development program; estimates regarding the
development timing for Lantern's drug candidates and ADC
development program; Lantern's research and development efforts of
its internal drug discovery programs and the utilization of its
RADR® platform to streamline the drug development
process; Lantern's intention to leverage artificial intelligence,
machine learning and genomic data to streamline and transform the
pace, risk and cost of oncology drug discovery and development and
to identify patient populations that would likely respond to a drug
candidate; estimates regarding potential markets and potential
market sizes; sales estimates for Lantern's drug candidates and its
plans to discover and develop drug candidates and to maximize their
commercial potential by advancing such drug candidates itself or in
collaboration with others. Any statements that are not statements
of historical fact (including, without limitation, statements that
use words such as "anticipate," "believe," "contemplate," "could,"
"estimate," "expect," "intend," "seek," "may," "might," "plan,"
"potential," "predict," "project," "target," "goal,"
"objective," "aim," "should," "will," "would," or the
negative of these words or other similar expressions) should be
considered forward-looking statements. There are a number of
important factors that could cause actual results to differ
materially from those indicated by the forward-looking statements,
such as (i) the impact of the COVID-19 pandemic, (ii) the risk
that none of Lantern's product candidates has received FDA
marketing approval, and Lantern may not be able to successfully
initiate, conduct, or conclude clinical testing for or obtain
marketing approval for its product candidates, (iii) the risk that
no drug product based on Lantern's proprietary RADR A.I. platform
has received FDA marketing approval or otherwise been incorporated
into a commercial product, and (iv) those other factors set forth
in the Risk Factors section in Lantern's Annual Report on Form 10-K
for the year ended December 31, 2020,
filed with the Securities and Exchange Commission on March 10, 2021. You may access Lantern's Annual
Report on Form 10-K for the year ended December 31, 2020 under the investor SEC filings
tab of its website at www.lanternpharma.com or on the
SEC's website at www.sec.gov. Given these risks and
uncertainties, neither Lantern nor Deep Lens can give any
assurances that such forward-looking statements will prove to be
accurate, or that any other results or events projected or
contemplated by such forward-looking statements will in fact occur,
and investors are cautioned not to place undue reliance on these
statements. All forward-looking statements in this press release
represent the respective judgment of Lantern and Deep Lens as of
the date hereof, and, except as otherwise required by law, Lantern
and Deep Lens disclaim any obligation to update any forward-looking
statements to conform the statement to actual results or changes in
their expectations.
Lantern Pharma Contacts:
Investor Relations
David Waldman, Crescendo
Communications, LLC
IR@lanternpharma.com
212-671-1021
Public Relations
Nicholas Koulermos, Vice President –
5W Public Relations
lantern@5wpr.com
646-843-1812
Deep Lens PR Contact:
Adrienne
Kemp, adriennekemppr@gmail.com
949-922-0801
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-enters-into-strategic-collaboration-with-deep-lens--partnership-expected-to-accelerate-enrollment-in-upcoming-phase-2-clinical-trial-for-never-smokers-with-non-small-cell-lung-cancer-301386715.html
SOURCE Lantern Pharma